Invention Grant
- Patent Title: Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
-
Application No.: US16564739Application Date: 2019-09-09
-
Publication No.: US11235031B2Publication Date: 2022-02-01
- Inventor: Anthony O. Caggiano , Anindita Ganguly , Jennifer Iaci , Tom Parry
- Applicant: Acorda Therapeutics, Inc.
- Applicant Address: US NY Ardsley
- Assignee: Acorda Therapeutics, Inc.
- Current Assignee: Acorda Therapeutics, Inc.
- Current Assignee Address: US NY Ardsley
- Agency: Elmore Patent Law Group, P.C.
- Agent Carolyn S. Elmore; Joseph C. Zucchero
- Main IPC: A61K38/18
- IPC: A61K38/18
Abstract:
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Public/Granted literature
Information query
IPC分类:
